Shares of Evoke Pharma Inc. (NASDAQ:EVOK) fell 10% during trading on Tuesday . The company traded as low as $2.30 and last traded at $2.34, with a volume of 935,245 shares traded. The stock had previously closed at $2.60.

A number of research firms have recently commented on EVOK. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research note on Tuesday, May 3rd. FBR & Co restated a “buy” rating on shares of Evoke Pharma in a report on Saturday, May 14th. Noble Financial restated a “hold” rating on shares of Evoke Pharma in a report on Tuesday. Brean Capital restated a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. Finally, Rodman & Renshaw cut Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock. in a report on Monday, July 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. Evoke Pharma presently has an average rating of “Hold” and an average target price of $13.34.

The firm’s market cap is $16.58 million. The firm’s 50-day moving average price is $4.67 and its 200 day moving average price is $4.70.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Monday, August 15th. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. Analysts expect that Evoke Pharma Inc. will post ($1.43) EPS for the current fiscal year.

In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the company’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.